Literature DB >> 6137019

Pharmacokinetics of chlorazepate after intravenous and intramuscular administration.

A Bertler, S Lindgren, J O Magnusson, H Malmgren.   

Abstract

Dichlorazepate (DPC) was given to eight healthy volunteers aged 22-38 years (five males and three females). The dose was 20 mg (48.9 mumol) given either as an IV or an IM injection. The interval between the injections was at least 1 week. Plasma samples were analysed for desmethyldiazepam (DMD) by HPLC before and after acid hydrolysis. The kinetics after both IV and IM administration could be explained by a one or two compartment open model. By comparing values before and after hydrolysis an estimate of di- and/or monopotassiumchlorazepate (MPC) could be made. The bioavailability was almost 100% after IM administration. The plasma half lives of DPC and DMD were independent of the form of administration (2.42 and 46.0 h respectively after IV and 2.29 and 45.1 h respectively after IM injection).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137019     DOI: 10.1007/bf00436160

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers.

Authors:  H M von Hattingberg; D Brockmeier; G Kreuter
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

2.  Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate.

Authors:  H R Ochs; D J Greenblatt; M D Allen; J S Harmatz; R I Shader; G Bodem
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

3.  Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.

Authors:  R I Shader; A Georgotas; D J Greenblatt; J S Harmatz; M D Allen
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

4.  Diazepam metabolism in normal man. I. Serum concentrations and clinical effects after intravenous, intramuscular, and oral administration.

Authors:  L Hillestad; T Hansen; H Melsom; A Drivenes
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

5.  Pharmacokinetics of the placental transfer and distribution of clorazepate and its metabolite nordiazepam in the feto-placental unit and in the neonate.

Authors:  E Rey; P Giraux; P d'Athis; J M Turquais; J Chavinie; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

6.  Pharmacokinetics of clorazepate in pregnant and non-pregnant women.

Authors:  E Rey; P d'Athis; P Giraux; D de Lauture; J M Turquais; J Chavinie; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

7.  Effect of antacids on absorption of clorazepate.

Authors:  A H Chun; P J Carrigan; D J Hoffman; R P Kershner; J D Stuart
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

8.  [Pharmacokinetic studies after oral and parenteral application of dipotassium chlorazepate (author's transl)].

Authors:  M Staak; A Moosmayer; K Besserer; K Speidel; A Kleinschmidt
Journal:  Arzneimittelforschung       Date:  1982

9.  Pharmacokinetics of dipotassium chlorazepate in patients after repeated 50 mg oral doses.

Authors:  A Bertler; S Lindgren; H Malmgren
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

  9 in total
  1 in total

1.  Intramuscular bioavailability of chlorazepate as compared to diazepam.

Authors:  A Bertler; S Lindgren; J O Magnusson; H Malmgren
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.